Relmada Therapeutics, Inc. (RLMD)

Market Cap	10.82M
Revenue (ttm)	n/a
Net Income (ttm)	-86.49M
Shares Out	30.17M
EPS (ttm)	-2.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	330,804
Open	0.390
Previous Close	0.363
Day's Range	0.350 - 0.400
52-Week Range	0.342 - 7.220
Beta	0.33
Analysts	Hold
Price Target	4.25 (+1,085.5%)
Earnings Date	Nov 7, 2024

About RLMD

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: RLMD
• Website: https://www.relmada.com

Analyst Forecast

According to 4 analysts, the average rating for RLMD stock is "Hold." The 12-month stock price forecast is $4.25, which is an increase of 1,085.50% from the latest price.

Price Target

$4.25

(1,085.50% upside)

Analyst Consensus: Hold